WallStreetZenWallStreetZen

NASDAQ: INDP
Indaptus Therapeutics Inc Stock Ownership - Who owns Indaptus Therapeutics?

OverviewForecastEarningsDividendOwnership

Insider buying vs selling

Have Indaptus Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Glen R. Anderson10% Owner2023-08-1423,934$2.34
$56.01kBuy
Glen R. Anderson10% Owner2023-08-1135,064$2.12
$74.34kBuy
Glen R. Anderson10% Owner2023-08-1044,354$1.94
$86.05kBuy
Boyan Vesselinov LitchevChief Medical Officer2022-12-01500$1.87
$935.50Buy
Boyan Vesselinov LitchevChief Medical Officer2022-11-22500$1.83
$915.00Buy
Jeffrey A. MecklerCEO and Director2022-11-219,600$1.90
$18.24kBuy
Jeffrey A. MecklerCEO and Director2022-11-18400$1.76
$705.60Buy

1 of 1

INDP insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when INDP insiders and whales buy or sell their stock.

INDP Shareholders

What type of owners hold Indaptus Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Dexcel Pharma Technologies Ltd50.41%4,234,897$11.48MInsider
Michael James Newman16.29%1,368,356$3.71MInsider
Glen R. Anderson15.53%1,304,318$3.53MInsider
Vanguard Group Inc2.98%250,348$678.44kInstitution
John W. Kozarich1.81%151,761$411.27kInsider
Investment House LLC1.29%108,282$293.44kInstitution
Jeffrey A. Meckler0.90%75,374$204.26kInsider
Anthony J. Maddaluna0.64%53,570$145.17kInsider
Geode Capital Management LLC0.60%50,521$136.91kInstitution
Strategy Asset Managers LLC0.54%45,336$122.86kInstitution

1 of 3

INDP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
INDP6.95%85.98%Net BuyingNet Buying
UNCY3.09%18.00%
SYBX22.46%77.54%Net Selling
GNPX6.45%12.22%Net Buying
KA3.93%96.07%Net BuyingNet Buying
View Top Biotech Stocks

Indaptus Therapeutics Stock Ownership FAQ

Who owns Indaptus Therapeutics?

Indaptus Therapeutics (NASDAQ: INDP) is owned by 6.95% institutional shareholders, 85.98% Indaptus Therapeutics insiders, and 7.07% retail investors. Dexcel Pharma Technologies Ltd is the largest individual Indaptus Therapeutics shareholder, owning 4.23M shares representing 50.41% of the company. Dexcel Pharma Technologies Ltd's Indaptus Therapeutics shares are currently valued at $11.48M.

If you're new to stock investing, here's how to buy Indaptus Therapeutics stock.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.